drugset / Trial / NCT00357968
Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting
Phase 2
Completed
201 enrolled
Eli Lilly and Company
Daiichi Sankyo · collabThe TIMI Study Group · collab
RandomizedCrossoverQuadruple-blindTreatment
Summary
The purpose of this study is to provide information of the relative potency of prasugrel and clopidogrel on platelet function studies, inflammation, and myocyte necrosis in subjects undergoing elective percutaneous coronary intervention (PCI).
Timeline
- Start
- 2006-08
- Primary completion
- 2007-06
- Completion
- 2007-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clopidogrel | Small molecule | 150 mg | Oral |
| Subject | Prasugrel | Small molecule | 10 mg | Oral |